Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer

Urology

Volumn 76, Issue 5, 2010, Pages 1175-1181

  Saad, Fred ^a   Eastham, James ^b  

^a NOTRE DAME HOSPITAL   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INCIDENCE; MALE; OVERALL SURVIVAL; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 78149356666     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.05.026     Document Type: Article

References (32)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics CA Cancer J Clin 59 2009 225 249
2. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
3. R.E. Coleman Skeletal complications of malignancy Cancer 80 1997 1588 1594
4. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
5. K.P. Weinfurt, Y. Li, and L.D. Castel The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 16 2005 579 584
6. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 2.2009: prostate cancer www.nccn.org/professionals/physician- gls/PDF/prostate.pdf Accessed March 26, 2009
7. M. Aapro, P.A. Abrahamsson, and J.J. Body Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 2008 420 432
8. F. Saad New research findings on zoledronic acid: survival, pain, and anti-tumour effects Cancer Treat Rev 34 2008 183 192
9. F. Saad, D.M. Gleason, and R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
10. F. Saad Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer Clin Prostate Cancer 4 2005 31 37
11. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med Singapore 23 1994 129 138
12. V. Barghout, L. Abetz, and R. Arbuckle Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status (abstract) J Clin Oncol 2006 24
13. L.S. Rosen, D. Gordon, and M. Kaminski Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
14. L.S. Rosen, D. Gordon, and N.S. Tchekmedyian Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial Cancer 100 2004 2613 2621
15. C.L. Vogel, R.H. Yanagihara, and A.J. Wood Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy Oncologist 9 2004 687 695
16. K.P. Weinfurt, K.J. Anstrom, and L.D. Castel Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer Ann Oncol 17 2006 986 989
17. C. Ripamonti, F. Fulfaro, and C. Ticozzi Role of pamidronate disodium in the treatment of metastatic bone disease Tumori 84 1998 442 455
18. P. Major, R. Cook, and B. Chen Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: a survival-adjusted cumulative incidence analysis (abstract) Proc Am Soc Clin Oncol 2004 23
19. A. Wardley, N. Davidson, and P. Barrett-Lee Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration Br J Cancer 92 2005 1869 1876
20. K.P. Weinfurt, L.D. Castel, and Y. Li Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions Med Care 42 2004 164 175
21. K.K. Yuen, M. Shelley, and W.M. Sze Bisphosphonates for advanced prostate cancer Cochrane Database Syst Rev 2006 CD006250
22. A. Lipton The safety of zoledronic acid Expert Opin Drug Saf 6 2007 305 313
23. ® (zoledronic acid) [summary of product characteristics] 2003 Novartis Europharm, Limited West Sussex, UK
24. C. Van Poznak The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer Cancer Invest 24 2006 110 112
25. A.O. Hoff, B.B. Toth, and K. Altundag Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826 836
26. C.L. Estilo, C.H. Van Poznak, and T. Wiliams Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy Oncologist 13 2008 911 920
27. American Dental Association, Council on Scientific Affairs Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations J Am Dent Assoc 137 2006 1144 1150
28. M.A. Dimopoulos, E. Kastritis, and C. Bamia Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 2009 117 120
29. C.I. Ripamonti, M. Maniezzo, and T. Campa Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates The experience of the National Cancer Institute of Milan Ann Oncol 20 2009 137 145
30. R. Weitzman, N. Sauter, and E.F. Eriksen Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patientsMay 2006 Crit Rev Oncol/Hematol 62 2007 148 152
31. F. Saad, J.D. Adachi, and J.P. Brown Cancer treatment-induced bone loss in breast and prostate cancer J Clin Oncol 26 2008 5465 5476
32. M.R. Smith, J. Eastham, and D.M. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012